PLEASANT PRAIRIE, Wis.–(BUSINESS WIRE)–On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow—the company’s new, state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin. Wisconsin Governor Tony Evers and U.S. Representative Bryan Steil (WI-01) attended the Project Tomorrow Grand Opening event.
“Today marks another milestone in our company’s continued mission to manufacture specialty and generic injectables right here in America,” said Mariam S. Darsot, CEO & President of Nexus Pharmaceuticals, Inc. “By investing in this new, state-of-the-art facility, Nexus has greatly expanded our capability to deliver dependable, life-saving treatments to millions of patients in need.”
The Phase I investment of $100 million supports a new, three-story manufacturing facility with cutting-edge technology, including an advanced isolator system and multiple lyophilization (freeze-drying) machines for maximum product protection and sterility. Construction of the facility began in August 2019 and was completed in 2021, with commercial production expected to commence in 2022. The construction and design of the building features eco-friendly green equipment and processes. The full, multi-phase project is expected to be completed in ten years, with an estimated total investment of $250 million.
Earlier this year, Nexus announced that it was ready to serve and support any efforts to increase vaccine manufacturing as a result of the Covid-19 pandemic. Due to the brand-new manufacturing capacity of the facility, Nexus would be able to maintain the production of existing products and simultaneously begin manufacturing vaccines, unlike other veteran drug manufacturers, which may have to sacrifice the production of one critical-need drug for another.
“Thank you to Nexus for choosing Wisconsin to build this incredible, state-of-the-art facility,” said Wisconsin Governor Tony Evers. “This new facility will bring with it the innovation that fosters long-term, economic success. Nexus stands ready to support global COVID-19 vaccine production—a capability that will be boosted as a result of this new manufacturing facility. Not only is Nexus committed to manufacturing quality, safe medicines, but they are also committed to creating the kinds of high-quality jobs that ensure the health and prosperity of families and communities throughout Wisconsin.”
“One lesson we have all learned in the last year is the importance of a domestic supply of pharmaceuticals and other critical health care products,” said U.S. Representative Bryan Steil. “This new facility represents an incredible investment not just in Wisconsin, but in Nexus’ commitment to providing life-saving medicines manufactured right here in America.”
The facility is expected to bring over 77 new jobs in a variety of job functions in fields of high-tech manufacturing and science by 2022, creating 400+ new local jobs long-term. To meet these needs, Nexus plans to partner with local institutions to provide job training and career and research opportunities.
About Nexus Pharmaceuticals, Inc.
Nexus Pharmaceuticals, Inc. is a US-based, woman-led, minority-owned healthcare company and certified diverse supplier, specializing in innovative processes to make difficult-to- manufacture specialty and generic injectables that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals, including our new state-of-the-art Wisconsin manufacturing facility, please visit https://www.nexuspharma.net/project-tomorrow/.
